Try a new search

Format these results:

Searched for:

department:Medicine. General Internal Medicine

recentyears:2

school:SOM

Total Results:

14801


Doctors Have Feelings, Too [Newspaper Article]

Ofri, Danielle
[...] today it was me with the white coat, and her with the death sentence. A senior resident rescued him before he had a cardiac arrest, then screamed her lungs out at me in front of the entire emergency room staff.
PROQUEST:2619606821
ISSN: 0362-4331
CID: 167366

MEAN PLATELET VOLUME IS SIGNIFICANTLY ASSOCIATED WITH SURVIVAL FOLLOWING PERCUTANEOUS CORONARY INTERVENTION AND CORONARY ARTERY BYPASS SURGERY [Meeting Abstract]

Shah, Binita; Oberweis, Brandon; Tummala, Lakshmi; Amoroso, Nicholas; Lobach, Iryna; Grossi, Eugene; Sedlis, Steven; Berger, Jeffrey
ISI:000302326701589
ISSN: 0735-1097
CID: 875422

Cheney recovering fromheart transplant [Newspaper Article]

Altman, Lawrence K; Grady, Denise
The issues Mr. Cheney considered included his risk of infection from the pump line to his heart, the risk of blood clots that can cause strokes and the
PROQUEST:2620438861
ISSN: 1486-8008
CID: 167370

For Cheney, Pros and Cons in New Heart [Newspaper Article]

Altman, Lawrence K; Grady, Denise
Dr. Reiner has cared for Mr. Cheney for many years at George Washington University Hospital in Washington. Because that hospital does not perform heart
PROQUEST:2617921091
ISSN: 0362-4331
CID: 167371

Second malignancies after multiple myeloma: from 1960s to 2010s

Thomas, Anish; Mailankody, Sham; Korde, Neha; Kristinsson, Sigurdur Y; Turesson, Ingemar; Landgren, Ola
Based on small numbers, recent reports from 3 randomized trials have consistently demonstrated more hematologic malignancies in patients treated with lenalidomide as maintenance (vs placebo). This fact has prompted concern and highlighted the association between multiple myeloma and second malignancies. Furthermore, an excess of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after multiple myeloma has been known for over 4 decades. Most prior studies have been restricted because of small numbers of patients, inadequate follow-up, and limitations of ascertainment of second malignancies. Although the underlying biologic mechanisms of AML/MDS after multiple myeloma are unknown, treatment-related factors are presumed to be responsible. Recently, an excess risk of AML/MDS was found among 5652 patients with IgG/IgA (but not IgM) monoclonal gammopathy of undetermined significance, supporting a role for disease-related factors. Furthermore, there is evidence to suggest that polymorphisms in germline genes may contribute to a person's susceptibility to subsequent cancers, whereas the potential influence of environmental and behavioral factors remains poorly understood. This review discusses current knowledge regarding second malignancies after multiple myeloma and gives future directions for efforts designed to characterize underlying biologic mechanisms, with the goal to maximize survival and minimize the risk for second malignancies for individual patients.
PMCID:3327452
PMID: 22310913
ISSN: 1528-0020
CID: 2199142

FLAGRANT CONDUCT The Story of Lawrence v. Texas: How a Bedroom Arrest Decriminalized Gay Americans [Newspaper Article]

Oshinsky, David
ISI:000301621200001
ISSN: 0028-7806
CID: 484382

Peripheral administration of poly I:C disrupts contextual fear memory consolidation and BDNF expression in mice

Kranjac, Dinko; McLinden, Kristina A; Koster, Kyle M; Kaldenbach, David L; Chumley, Michael J; Boehm, Gary W
In the current study, administration of poly I:C induced a deficit in contextual, but not auditory-cue, fear memory consolidation. This memory deficit coincided with a decrease in hippocampal and cortical BDNF mRNA expression. These results extend prior work, and suggest that a single peripheral injection of poly I:C disrupts contextual fear memory consolidation processes in adult mice, and that these deficits may potentially be mediated by diminished BDNF expression.
PMID: 22222172
ISSN: 1872-7549
CID: 4960712

Epidemiologic consequences of microvariation in Mycobacterium tuberculosis

Mathema, Barun; Kurepina, Natalia; Yang, Guibin; Shashkina, Elena; Manca, Claudia; Mehaffy, Carolina; Bielefeldt-Ohmann, Helle; Ahuja, Shama; Fallows, Dorothy A; Izzo, Angelo; Bifani, Pablo; Dobos, Karen; Kaplan, Gilla; Kreiswirth, Barry N
BACKGROUND: Evidence from genotype-phenotype studies suggests that genetic diversity in pathogens have clinically relevant manifestations that can impact outcome of infection and epidemiologic success. We studied 5 closely related Mycobacterium tuberculosis strains that collectively caused extensive disease (n = 862), particularly among US-born tuberculosis patients. METHODS: Representative isolates were selected using population-based genotyping data from New York City and New Jersey. Growth and cytokine/chemokine response were measured in infected human monocytes. Survival was determined in aerosol-infected guinea pigs. RESULTS: Multiple genotyping methods and phylogenetically informative synonymous single nucleotide polymorphisms showed that all strains were related by descent. In axenic culture, all strains grew similarly. However, infection of monocytes revealed 2 growth phenotypes, slower (doubling approximately 55 hours) and faster ( approximately 25 hours). The faster growing strains elicited more tumor necrosis factor alpha and interleukin 1beta than the slower growing strains, even after heat killing, and caused accelerated death of infected guinea pigs ( approximately 9 weeks vs 24 weeks) associated with increased lung inflammation/pathology. Epidemiologically, the faster growing strains were associated with human immunodeficiency virus and more limited in spread, possibly related to their inherent ability to induce a strong protective innate immune response in immune competent hosts. CONCLUSIONS: Natural variation, with detectable phenotypic changes, among closely related clinical isolates of M. tuberculosis may alter epidemiologic patterns in human populations.
PMCID:3415951
PMID: 22315279
ISSN: 0022-1899
CID: 891622

Safety of new obesity drug requires more FDA study [Newspaper Article]

Siegel, Marc
Phentermine is an effective weight-loss drug that suppresses appetite. Though it can increase heart rate and blood pressure and cause palpitations, for many patients, it is well tolerated. The concerns with Qnexa center on its other main ingrethent - topiramate. Those concerns caused the FDA to reject Qnexa less than two years ago. So what has changed the momentum from FDA rejection to possible approval? It surely wasn't a study, completed late last year, which showed topiramate doubles the risk of cleft lip and palate in newborns of mothers who were taking the drug. The new FDA panel virtually ignored the results of this study, accepting the reassurances of Qnexa's manufacturer, Vivus, that it will restrict the drug for pregnant women and perform studies after approval to assess heart safety.
PROQUEST:2638149801
ISSN: 0739-0319
CID: 167357

Impact of an online prescription management account on medication adherence

Hou, John G; Murphy, Patricia; Tang, Andrew W; Khandelwal, Nikhil; Duncan, Ian; Pegus, Cheryl L
OBJECTIVES: To assess medication adherence rates of patients utilizing an online prescription management account compared with nonusers. STUDY DESIGN: A retrospective analysis was conducted using de-identified pharmacy claims data from a pharmacy benefit manager covering the period from April 1, 2009, to March 31, 2011. Patients who were continuously eligible throughout the study period and that had at least 1 prescription fill for any of the 8 therapeutic groups examined in the study were selected for inclusion. METHODS: Adherence was assessed by measuring the proportion of days covered (PDC). Propensity score matching was utilized to minimize differences in age, gender, chronic condition score, copay, household income, and urban locality between the users and nonusers groups. Results were reported for all therapeutic groups combined, as well as by individual therapeutic group. RESULTS: Overall, patients utilizing the online account had a significantly higher weighted average PDC (73.19% vs 61.64%, P <.0001). Users also had a higher average PDC for each individual therapeutic group, although the beta-blocker group was not statistically significant. The percentage of patients achieving an average PDC of >80% was also found to be greater in the users group across each therapeutic group and overall. CONCLUSIONS: Patients who utilized an online prescription management account had higher rates of medication adherence as compared with nonusers. Additional studies are needed to assess which specific components of the prescription management account have the biggest impact on adherence.
PMID: 22435965
ISSN: 1088-0224
CID: 1410322